Using 2 real-world clinical scenarios, this commentary focuses on practical strategies to manage pulmonary and endocrine adverse events associated with checkpoint inhibition in melanoma.
This commentary describes 2 cases from my clinic and our experience managing hepatic, neurologic, and hematologic adverse events in patients treated for melanoma with immune checkpoint inhibitors.
How do preexisting autoimmune conditions such as ulcerative colitis and rheumatoid arthritis affect management of melanoma with checkpoint inhibitors?
In this CME-certified educational module, CCO’s expert faculty members highlight case-based examples to discuss the management of adverse events during checkpoint inhibitor therapy.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.